Respiratory syncytial virus – Page 2

Pfizer Secures FDA Approval to Expand RSV Vaccine Abrysvo for High-Risk Adults Aged 18-59

6 months ago talkbio0Tagged Abrysvo, Approved, High-Risk Adults, immunocompromised adults, Pfizer, Respiratory syncytial virus, United States Food and Drug Administration, Vaccines

Pfizer, RSV vaccine, Abrysvo, FDA approval, high-risk adults, immunocompromised adults

Breakthroughs in RSV Prevention: Merck and Pfizer Report High Efficacy Rates

6 months ago talkbio0Tagged Abrysvo, Clesrovimab, Merck, Monoclonal Antibodies, Pfizer, Respiratory syncytial virus, RSV prevention, Vaccines

RSV prevention, Merck, Pfizer, clesrovimab, ABRYSVO, respiratory syncytial virus, monoclonal antibodies, vaccines

Merck’s RSV Antibody Clesrovimab Shows Promising Efficacy in Late-Stage Trial

6 months ago talkbio0Tagged Antibodies, Clesrovimab, Co., Infant, Late-Stage Trial, Respiratory syncytial virus

Merck & Co., RSV antibody, Clesrovimab, Respiratory syncytial virus, Infant protection, Late-stage trial results

Merck’s Clesrovimab Shows Promising Results in Preventing RSV Disease and Hospitalizations in Infants

6 months ago talkbio0Tagged Clesrovimab, Clinical Trials, Co., Monoclonal Antibodies, Respiratory syncytial virus

Clesrovimab, Respiratory Syncytial Virus (RSV), RSV Disease Prevention, Infant Health, Monoclonal Antibody, Clinical Trials, Merck & Co.

Pfizer Terminates Development of Oral RSV Medication Sisunatovir Due to Ongoing Challenges

7 months ago talkbio0Tagged Acquisition (action), Clinical Development, Pfizer, Respiratory syncytial virus, ReViral, RSV, sisunatovir, Termination - Inactive Reason Code

Pfizer, ReViral, RSV, Sisunatovir, Acquisition, Clinical Development, Termination

Enanta Pharmaceuticals Achieves Breakthrough in RSV Treatment with EDP-323, Demonstrating Significant Reductions in Viral Load and Symptoms

7 months ago talkbio0Tagged Alleviation, antiviral treatment, EDP-323, Enanta, Human Challenge Study, phase 2a, Respiratory syncytial virus, Symptoms, Viral Load result

Enanta Pharmaceuticals, EDP-323, Respiratory Syncytial Virus (RSV), Antiviral Treatment, Phase 2a Human Challenge Study, Viral Load Reduction, Symptom Alleviation

Vicebio Secures $100 Million Funding to Advance Multivalent Respiratory Virus Vaccines

7 months ago talkbio0Tagged Combo, Human Metapneumovirus, Molecular Clamp Technology, multivalent, Respiratory syncytial virus, Respiratory viruses, Series B funding round, Vaccines, Vicebio

Vicebio, Multivalent Respiratory Virus Vaccines, $100 Million Funding, Series B Funding Round, Molecular Clamp Technology, RSV and hMPV Vaccine Combo

GSK Advances Co-Administration of RSV and Shingles Vaccines with Positive Phase III Data

7 months ago talkbio0Tagged Adult, Arexvy, co-administration, Herpes zoster disease, Immunization, Phase III data, Respiratory syncytial virus, Shingrix, SmithKline Beecham, Vaccines

GSK, RSV vaccine, Shingles vaccine, Arexvy, Shingrix, co-administration, Phase III data, adult immunization

Enhanced Manufacturing Efforts by Sanofi and AstraZeneca Aim to Prevent Beyfortus Shortfalls in 2024

7 months ago talkbio0Tagged AstraZeneca, Beyfortus, chain management, Manufacture, Monoclonal Antibodies, Respiratory syncytial virus, sanofi

Beyfortus, RSV prevention, monoclonal antibody, Sanofi, AstraZeneca, manufacturing efforts, supply chain management

Pfizer Strengthens Case for RSV Vaccine with Positive Data in Vulnerable Adults

8 months ago talkbio0Tagged Abrysvo, Clinical Trials, Immune response, immunocompromised adults, Pfizer, regulatory approval, Respiratory syncytial virus, Vaccines

Pfizer, RSV vaccine, Abrysvo, immunocompromised adults, clinical trial, immune responses, regulatory approval